Where category 2 NGT plants and products are to be deliberately released or placed on the market, they should remain subject to a consent or authorisation and other provisions, including provisions on measures necessary to protect human and animal health and the environment such as modification, suspension and revocation of authorisation and emergency measures, in accordance with Directive 2001/18/EC or Regulation (EC) No 1829/2003. However, given the wide variety of category 2 NGT plants, the amount of information necessary for the risk assessment will vary on a case-by-case basis. The Authority recommended flexibility in data requirements for the risk assessment of plants obtained through cisgenesis and targeted mutagenesis in its scientific opinions ‘Applicability of the EFSA Opinion on site-directed nucleases type 3 for the safety assessment of plants developed using site-directed nucleases type 1 and 2 and oligonucleotide-directed mutagenesis’ of 2020 and ‘Updated scientific opinion on plants developed through cisgenesis and intragenesis’ of 2022. On the basis of the Authority’s statement on ‘criteria for risk assessment of plants produced by targeted mutagenesis, cisgenesis and intragenesis’ of 2022, considerations on the history of safe use, familiarity for the environment and the function and structure of the modified or inserted sequences should assist in determining the type and amount of data required to perform the risk assessment of category 2 NGT plants. It is therefore necessary to establish general principles and information requirements for the risk assessment of these plants, while providing for flexibility and possibility to adapt risk assessment methodologies to scientific and technical progress.
Recital 37, Regulation (EU) 2026/1388
In forcesince 17 Jun 2026